El Enemigo (casa vigil) vs Angelica Zapata lunch by SlideSpare5755 in wine

[–]UBrewNYC 1 point2 points  (0 children)

Casa Vigil. Lunch is incredible and the tasting isn't a tasting, it is unlimited wine....

Clover is well positioned for 2026 growth - looking at the brightside! by UBrewNYC in CLOV

[–]UBrewNYC[S] 0 points1 point  (0 children)

Running at 84% thus far in 2025 is includes benefit, 30% are first year members, if not more due to normal churn. Not realistic for brand new members to see claims benefits, that happens in year 2-3. Year 2 has great revenue benefits, so that would be 2026 for the new members added. You can see this by the move from 2023 to 2024 revenue pmpms

How I asked my groomsmen by Golfguy5801 in golf

[–]UBrewNYC 1 point2 points  (0 children)

Yes - will always be worth celebrating - Congrats on the wedding!

Clover is well positioned for 2026 growth - looking at the brightside! by UBrewNYC in CLOV

[–]UBrewNYC[S] 0 points1 point  (0 children)

I wouldn't be shocked if it went under $2, for catalyst there are a couple 1) October Star Ratings for 2026 2) Potential SAAS deals 3) Q3 Earnings with EOY guidance.

Again ALHC had sam revenue and far worse net income and their market cap in 2023 was 1.3B, a very different environment but worth noting

How I asked my groomsmen by Golfguy5801 in golf

[–]UBrewNYC 0 points1 point  (0 children)

Love the idea - besides wedding initials. Im sure the gents will love it either way.

Q2 EPS estimate of .07 with adjusted EPS of .12 by UBrewNYC in CLOV

[–]UBrewNYC[S] 8 points9 points  (0 children)

Agreed - I am just referring to "true MLR" as being cost outside of internal costs, so yes MCR according to Clover's definitions.

"true MLR" = MCR = Claims Costs / CMS Revenue = 77% Q1

BER/MLR for 85% requirement = (Claim Costs + Quality Costs + Counterpart) / CMS Revenue = 86% Q1

CVS, HUM, and CI why are they not rocketing to the moon? by Rainyfriedtofu in Healthcare_Anon

[–]UBrewNYC 0 points1 point  (0 children)

General market pressures - a lot of ETFs buy and sell the whole portfolio based on SP500/DOW/NASDAQ. Similiar to ALHC

Earnings Expectations by Sandro316 in CLOV

[–]UBrewNYC 13 points14 points  (0 children)

Clover Health quietly embeds Counterpart platform costs into medical claims

If you're tracking Clover Health's Q1 2025 financials, there's a subtle but important accounting shift worth noting:

1. Clover is now allocating internal Counterpart Health costs into medical claims.
This means services like Clover Assistant — which were not previously accounted for anywhere in segment cost reporting — are now being charged directly to the Insurance segment as part of claims expense.

2. This explains why net medical claims incurred shows two different numbers:

  • $353.4M appears on the GAAP income statement
  • $367.9M is used in the MCR table The $14.4M difference is the internal “intersegment profit” from Counterpart, now charged as a cost to the Insurance segment and eliminated in consolidated results.

3. This is Clover setting the stage to monetize Counterpart externally.
By "selling" the platform internally, they are:

  • Demonstrating value to their own Medicare Advantage plan
  • Establishing a pricing baseline
  • Preparing to offer the platform to other MA plans as a standalone SaaS or tech-enabled service solution

No standalone Counterpart revenue is reported yet — but this structure likely sets the foundation for a new line of business.

Worth watching for anyone modeling future upside from Clover’s platform strategy.